McKesson stock heads into the open after a 1.5 percent slide
Published on 09/09/2026 at 06:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 4, 2026, McKesson stock ended at USD 907.99 on the NYSE, a decline of 1.5 percent from the previous close of USD 921.38. According to market data, the shares traded between roughly USD 907 and USD 921 during the session, with volume near 879,000 shares, while the S&P 500 lost about 0.4 percent on the same date.
September 4, 2026 in numbers
McKesson Corp. (ISIN US58155Q1031, NYSE: MCK) closed the September 4, 2026 session at USD 907.99, down USD 13.39 or 1.45 percent compared with the prior close of USD 921.38, based on the official NYSE closing data cited by Barrons market overview. The trading range for the day ran from an intraday low near USD 907.99 to a high close to USD 921, with reported turnover of about 879,000 shares, roughly 86% of the recent 65 day average volume. On the broader market side, the S&P 500 benchmark index finished the same session down about 0.4 percent, highlighting that McKesson underperformed the large cap average in that risk off environment, according to Zacks stock market wrap. Sector commentary on September 8, 2026 from MarketBeat analysis noted strong growth in McKesson's oncology and multi specialty operations and a potential USD 2.25 billion precision medicine deal, suggesting that investors are weighing long term growth drivers against shorter term market volatility rather than reacting to a single company specific data point for the September 4, 2026 move.
Healthcare conference appearance today
Today, September 9, 2026, McKesson is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, with management presenting at 8:00 a.m. ET, according to the event transcript published by Seeking Alpha. The appearance offers management an opportunity to update institutional investors on strategic priorities, capital allocation and the outlook for key segments such as oncology distribution and precision medicine partnerships, themes highlighted in the recent commentary on the potential USD 2.25 billion precision medicine deal and first quarter growth trends reported by MarketBeat. In addition to company specific news, broader macro factors remain in play today after the recent session in which the S&P 500 and Dow Jones Industrial Average both declined, as described by Pittsburgh Post Gazette market report, a backdrop that may continue to shape sentiment toward defensive healthcare distributors such as McKesson as trading resumes ahead of the opening bell.
